GLP-1 and Your Mental Health: Depression, Anxiety, and the FDA Safety Review

How the Investigation Started

In July 2023, the FDA began investigating reports of suicidal thoughts and self-harm behavior in patients taking GLP-1 receptor agonists. The European Medicines Agency launched a parallel investigation. Postmarketing reports — primarily involving semaglutide and liraglutide — had been submitted to adverse event databases, raising concern about a potential psychiatric safety signal.

The weight-loss medications Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) already carried language about suicidal ideation risk in their Warnings and Precautions sections — inherited from older weight-loss drugs with known psychiatric effects.

What the FDA Found

In January 2024, the FDA issued a preliminary communication stating that its initial evaluation had not found evidence that GLP-1 medications cause suicidal thoughts or actions. But because individual clinical trials had too few events to draw definitive conclusions, the FDA conducted a comprehensive meta-analysis to increase statistical power.

That meta-analysis — covering 91 placebo-controlled trials with over 107,000 patients — found no increased risk of psychiatric adverse events with GLP-1 receptor agonists. A large retrospective cohort study comparing GLP-1 users to SGLT2 inhibitor users also found no increased risk of intentional self-harm.

Based on these findings, in January 2026, the FDA took the unusual step of requesting that manufacturers remove the suicidal ideation and behavior warning from GLP-1 medication labels — the opposite of adding a new warning. The affected products were Saxenda, Wegovy, and Zepbound.

Why Mental Health Still Matters on GLP-1s

Even though GLP-1 medications themselves don't appear to increase psychiatric risk, significant weight loss can affect mental health through other pathways. Rapid changes in body image, altered social dynamics, shifts in food-related coping mechanisms, and the neurological effects of caloric restriction can all affect mood and psychological well-being.

Some patients report feeling a sense of loss around food — previously a source of comfort or social connection — even as they benefit from weight loss. Others experience anxiety about weight regain. These are normal psychological responses to a major life change, not medication side effects.

There's also emerging research suggesting GLP-1 medications may have positive psychiatric effects. Some studies have found improvements in depressive symptoms, cognitive function, and quality of life in GLP-1 users — potentially mediated through anti-inflammatory effects and improved metabolic health.

What Your Doctor Should Screen For

A responsible prescriber should assess mental health at baseline and during treatment. This doesn't require a formal psychiatric evaluation for every patient, but it does mean asking about your mood, sleep quality, and emotional relationship with food. Validated screening tools like the PHQ-2 or PHQ-9 for depression take less than two minutes to administer.

If you have a history of depression, anxiety, eating disorders, or substance use, your provider should know before starting GLP-1 therapy — not because the medication will worsen these conditions, but because significant weight loss and dietary changes can interact with existing mental health patterns in ways that benefit from monitoring.

When to Speak Up

Tell your provider if you notice persistent changes in mood, sleep, or motivation. If you find yourself losing interest in activities you previously enjoyed, feeling unusually irritable or tearful, or having thoughts of self-harm, reach out to your prescribing provider or a mental health professional. The 988 Suicide & Crisis Lifeline is available 24/7 by calling or texting 988.

These conversations are not about blaming the medication — they're about ensuring you get comprehensive care that addresses your physical and mental well-being together.

The Takeaway

The FDA's investigation is complete, and the data is clear: GLP-1 medications do not increase the risk of suicidal ideation or behavior. The warning has been removed from product labels. But mental health monitoring during any significant weight loss journey remains good clinical practice — and your provider should make space for those conversations at every visit.